Compare FOR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | GHRS |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2007 | 2021 |
| Metric | FOR | GHRS |
|---|---|---|
| Price | $30.31 | $14.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $31.75 | ★ $32.90 |
| AVG Volume (30 Days) | 197.6K | ★ 223.0K |
| Earning Date | 01-20-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $1,685,000,000.00 | N/A |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | ★ 15.89 | N/A |
| 52 Week Low | $18.00 | $7.98 |
| 52 Week High | $30.74 | $19.51 |
| Indicator | FOR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 45.48 |
| Support Level | $29.13 | $14.50 |
| Resistance Level | $29.87 | $15.88 |
| Average True Range (ATR) | 0.95 | 0.89 |
| MACD | 0.32 | -0.19 |
| Stochastic Oscillator | 93.22 | 35.60 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.